Infections with organisms that produce the Klebsiella pneumoniae carbapenemase (KPC) are associated with therapeutic failure and high mortality rates. Complicating patient treatment is the inability to accurately detect KPC producers in the clinical laboratory using the guidelines suggested for susceptibility testing. Little is known about the role gene expression plays in KPC-mediated resistance or how the level of expression may affect susceptibility testing. Hydrolysis of carbapenems by KPCs has been demonstrated in vitro (1, 21, 22) ; however, multiple studies have reported variability in susceptibility testing of KPC-producing clinical isolates (2, 3, 13, 22) . Although variation in KPC enzyme production could contribute to the variability seen during susceptibility testing, it is difficult to assess the influence of the KPC ␤-lactamase on susceptibility testing using clinical isolates which may harbor multiple ␤-lactamases and may have alterations in outer membrane proteins (4, 7, 9, 10, 21, 24) . Therefore, we used cloning and transformation to create a panel of four different genera of Gram-negative bacteria that expressed the bla KPC gene without the influence of other resistance mechanisms. We evaluated the relationship between bla KPC gene expression and copy number with ␤-lactam MICs among the transformants and compared bla KPC gene expression and copy numbers among clinical isolates known to carry bla KPC .
To construct transformants expressing bla KPC , a 1,314-bp fragment including the bla KPC-2 structural gene and 363 bp of the adjacent upstream region was amplified by PCR and sequenced. The bla KPC-2 product was cloned into pCR2.1 (Invitrogen) and subcloned into the broad host vector pMP220 (20) . Escherichia coli K-12 259, K. pneumoniae 23, Enterobacter cloacae ATCC 13047, and Pseudomonas aeruginosa PAO1 were transformed with pMP220-KPC-2 by electroporation (22) . In addition, 10 KPC-producing clinical isolates were evaluated, including two isolates of E. coli (233 and 236), four isolates of K. pneumoniae (UMM3, V110984, HUH6, and HUH40), one Enterobacter sp. isolate (01MGH049), and three isolates of P. aeruginosa (PS5, PS17B, and PS28) ( Table 1) .
Isoelectric focusing revealed that these clinical isolates produced multiple ␤-lactamases, which included enzymes with pIs equivalent to those of OXA, SHV-5, SHV-2, and TEM-1 in addition to KPC (22) . Antimicrobial susceptibility testing was performed using agar dilution and interpreted using 2010 CLSI breakpoints (5, 6) . The impact of KPC production on susceptibility varied with respect to the drug and transformant analyzed (Table 1) . When K. pneumoniae pMP220-KPC-2 is evaluated, the ceftazidime and cefepime MICs are interpreted to be in the susceptible range (5) using 2010 CLSI breakpoints. These data underscore the potential difficulty in detecting KPC-producing K. pneumoniae using phenotypic methodologies. As expected, ␤-lactam MICs varied among the clinical isolates.
Prior to evaluating bla KPC gene expression, relative bla KPC copy number was determined (19) . For the KPC-2 transformants, the copy number of the gene varied among the different genetic backgrounds despite the use of the same shuttle vector, pMP220. The copy numbers for bla KPC in the transformants ranged from 2 to 26 (Table 1) . Nine of 10 clinical isolates had one or two copies of bla KPC , with the exception of K. pneumoniae HUH40, which had five copies of bla KPC .
Increases in gene copy number have been correlated with increases in ␤-lactamase gene expression and increases in ␤-lactam MICs (15) . To determine whether bla KPC copy number correlated with bla KPC gene expression, the relative expression of each bla KPC transcript was evaluated for the clinical isolates and compared to the expression observed for the KPC-2 transformants using real-time reverse transcription (RT)-PCR (12, 15, 18) . The clinical isolates of E. coli and P. aeruginosa and three K. pneumoniae isolates (UMM3, V110984, and HUH6) all had bla KPC-2 expression levels lower than their respective KPC-2 transformants. Surprisingly, a 1:1 ratio between copy number and bla KPC expression was not observed except for the E. cloacae KPC-2 transformant and 01MGH049 and the K. pneumoniae KPC-2 transformant and HUH40 (Table 1) .
Due to the discrepancies between gene copy numbers and expression, it was possible that the entire promoter responsible for bla KPC expression was not present in the transformants. Therefore, to map the bla KPC promoter region, the start sites of transcription were determined for nine of the clinical isolates and compared to the start sites for the KPC-2 transformants using 5Ј RACE (rapid amplification of cDNA ends) (22) . These data revealed that the transcriptional start sites for the four transformants and eight of the clinical isolates were identical, indicating that the entire bla KPC promoter was present in each transformant. The primary start site identified for all of the transformants and eight of the clinical isolates was an adenine residue 286 bp upstream of the translational start codon (Fig. 1) . This start site did not correspond to the previously mapped start site observed by Yigit et al. or the start sites predicted by Gootz et al. (8, 23) . The data presented here mapped the putative Ϫ10 and Ϫ35 promoter elements as TATCTT and TTGACA, respectively, separated by a 19-bp spacer, which correlated with 70 consensus promoter elements found for E. coli (11, 14) . A second start site not previously identified was mapped to a thymine residue 140 bp upstream of the translational start codon with putative Ϫ10 and Ϫ35 promoter elements of TACCAA and TGGAC. A 68-bp deletion in the upstream region of K. pneumoniae V110984 resulted in a start site of transcription with putative Ϫ10 and Ϫ35 elements that are less than consensus to those for 70 of E. coli. Only one start site was observed for bla , which suggests a different type of transcriptional regulation (22) . Taken together, these data demonstrate the level of complexity by which bla KPC is regulated and could represent a means of differential expression under different selective pressures.
This study demonstrated the contribution of KPC-2 to ␤-lactam susceptibility in four different genera. The gene copy numbers or bla KPC expression levels evaluated in the absence of selective pressure could not explain the variation in susceptibility patterns in the KPC-2 transformants or clinical isolates. These data suggest that additional mechanisms aside from gene expression and copy number contribute to the variability in susceptibility when testing KPC-producing isolates. Typical experimental approaches to understand the underlying mechanisms associated with these organisms have been unsuccess- 
